I-Mab Biopharma: going global with innovative biologics

With its two-pronged approach, I-Mab Biopharma is developing biological therapeutics indicated for cancer and autoimmune diseases for the Chinese market and for the rest of the world.

Go to the profile of I-Mab Biopharma
Sep 12, 2019
0
0
Page of
Go to the profile of I-Mab Biopharma

I-Mab Biopharma

I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics of first-in-class or best-in-class potential in the therapeutic areas of immuno-oncology and autoimmune diseases. I-Mab's mission is to bring transformational medicines to patients through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D capabilities and global partnerships. The company is on track to become a fully integrated end-to-end global biopharmaceutical company with world-class innovative discovery expertise, fit-for-purpose technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. I-Mab is well-recognized by capital markets to have successfully raised over US$400 million in equity financing since its establishment in 2016. Its recent USD 200 million Series C financing represents one of the largest amounts ever raised by a biotech company in China.

No comments yet.